Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Empiric Definition of Eligibility Criteria for Clinical Trials in Relapsed/Refractory AML: Analysis of 1,892 Patients from HOVON/SAKK and SWOG

Roland B. Walter, MD PhD MS, Megan Othus, PhD, Bob Löwenberg, MD PhD, Gert J Ossenkoppele, MD PhD, Stephen H. Petersdorf, MD, Thomas Pabst, MD, Marie-Christianne Vekemans, MD, Frederick R. Appelbaum, MD, Harry P. Erba, MD PhD, Elihu H. Estey, MD

Blood (2014) 124 (21): 3676.

https://doi.org/10.1182/blood.V124.21.3676.3676

Published: 2014

Journal Articles

A Phase I/II Study Of Fludarabine, Cyclophosphamide, Rituximab and Vorinostat Followed By Rituximab and Vorinostat Maintenance Therapy In Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia (CLL) Or Small Lymphocytic Leukemia (SLL)

Raya Mawad, MD, Ajay K. Gopal, MD, Oliver W. Press, MD, PhD, David G. Maloney, MD, PhD, Stephen H. Petersdorf, MD, Troy Wadsworth, MD, Trevor W. Dennie, MD, Yoshio Inoue, MD, Karl J. Schultheiss, MD, Kiarash Kojouri, MD, MPH, Kelly M. Smith, MD, Britt Kammerer, John M. Pagel, MD, PhD

Blood (2013) 122 (21): 4191.

https://doi.org/10.1182/blood.V122.21.4191.4191

Published: 2013

Journal Articles

A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia

Stephen H. Petersdorf, Kenneth J. Kopecky, Marilyn Slovak, Cheryl Willman, Thomas Nevill, Joseph Brandwein, Richard A. Larson, Harry P. Erba, Patrick J. Stiff, Robert K. Stuart, Roland B. Walter, Martin S. Tallman, Leif Stenke, Frederick R. Appelbaum

Blood (2013) 121 (24): 4854–4860.

https://doi.org/10.1182/blood-2013-01-466706

Published: 2013

Journal Articles

Specific Features Identify Patients with Relapsed/Refractory Mantle Cell Lymphoma Benefitting From Autologous Hematopoietic Cell Transplantation.

Ryan D. Cassaday, MD, Katherine A. Guthrie, PhD, Lihua E. Budde, MD, PhD, Leslie Thompson, Brian G. Till, MD, Oliver W. Press, MD, PhD, Thomas Chauncey, MD, PhD, John M. Pagel, MD, PhD, Stephen H. Petersdorf, MD, William I. Bensinger, MD, Leona Holmberg, MD, PhD, Andrei R. Shustov, MD, Damian J. Green, MD, Edward N. Libby, III, MD, David G. Maloney, MD, PhD, Ajay K. Gopal, MD

Blood (2012) 120 (21): 3082.

https://doi.org/10.1182/blood.V120.21.3082.3082

Published: 2012

Journal Articles

Survival After Failure of Initial Therapy for Newly-Diagnosed or Relapsed/Refractory AML At An Academic Center: Subsequent Clinical Trial Vs. Not

Ravinder K Sandhu, Jack M. Lionberger, MD, PhD, Megan Othus, PhD, John M. Pagel, MD, PhD, Kathleen ShannonDorcy, RN, PhD, Paul C. Hendrie, MD, PhD, Stephen H. Petersdorf, MD, Pamela S Becker, MD, PhD, Frederick R. Appelbaum, M.D., Elihu H Estey, MD

Blood (2011) 118 (21): 1497.

https://doi.org/10.1182/blood.V118.21.1497.1497

Published: 2011

Journal Articles

Probability of Eventual CR After Course 1 of Induction Therapy for Newly-Diagnosed AML As a Function of Speed of Neutrophil and Platelet Recovery

Laura F Newell, MD, Ravinder K Sandhu, Pamela S Becker, MD, PhD, John M. Pagel, MD, PhD, Paul C. Hendrie, MD, PhD, Roland B. Walter, MD, PhD, Stephen H. Petersdorf, MD, Kathleen Shannon Dorcy, RN, MN, Ph.C, Janis L. Abkowitz, MD, Frederick R. Appelbaum, MD, Elihu H. Estey, MD

Blood (2011) 118 (21): 1498.

https://doi.org/10.1182/blood.V118.21.1498.1498

Published: 2011

Journal Articles

Prognostic Import of French-American-British (FAB) System As Embedded in 2008 Revision of World Health Organization Classification of AML: Review of SWOG Data

Laura F Newell, MD, Megan Othus, PhD, Roland B. Walter, MD, PhD, Stephen H. Petersdorf, MD, Thomas Chauncey, MD, PhD, Jeanne E. Anderson, MD, John E. Godwin, MD, MS, Kenneth J. Kopecky, PhD, Frederick R. Appelbaum, MD, Elihu H. Estey, MD

Blood (2011) 118 (21): 1446.

https://doi.org/10.1182/blood.V118.21.1446.1446

Published: 2011

Journal Articles

KIT Mutations Are Rare Among Elderly AML Patients: A SWOG Report

Fabiana Ostronoff, MD, Megan Othus, PhD, Phoenix A. Ho, MD, Stephen H. Petersdorf, MD, Jeanne E. Anderson, MD, John E. Godwin, MD, MS, Cheryl L Willman, MD, Jerald P. Radich, MD, Frederick R. Appelbaum, MD, Derek L. Stirewalt, MD, Soheil Meshinchi, MD, PhD

Blood (2011) 118 (21): 2510.

https://doi.org/10.1182/blood.V118.21.2510.2510

Published: 2011

Journal Articles

The Pre-Transplant Mantle Cell Lymphoma International Prognostic Index Predicts Overall and Progression-Free Survival Following High-Dose Therapy and Autologus Stem Cell Transplant for Mantle Cell Lymphoma

Leslie A Thompson, Katherine A Guthrie, Lihua Elizabeth Budde, MD, PhD, Brian G. Till, MD, Oliver W. Press, MD, PhD, Thomas Chauncey, MD, PhD, John M. Pagel, MD, PhD, Stephen H. Petersdorf, MD, William I Bensinger, MD, Leona Holmberg, MD., PhD, Andrei R. Shustov, MD, Damian J. Green, MD, David G. Maloney, MD, PhD, Ajay K. Gopal, MD

Blood (2011) 118 (21): 2026.

https://doi.org/10.1182/blood.V118.21.2026.2026

Published: 2011

Journal Articles

Prevalence and Clinical Implications of IDH2 R140 and R172 Mutations in Older Adults with AML: A Report From SWOG,

Phoenix A. Ho, MD, Megan Othus, PhD, Fabiana Ostronoff, MD, Stephen H. Petersdorf, MD, Jeanne E. Anderson, MD, John E. Godwin, MD, MS, Cheryl L Willman, MD, Jerald P. Radich, MD, Frederick R. Appelbaum, MD, Derek L. Stirewalt, MD, Soheil Meshinchi, MD, PhD

Blood (2011) 118 (21): 3516.

https://doi.org/10.1182/blood.V118.21.3516.3516

Published: 2011

Journal Articles

DNMT3A Mutations Independently Predict Poor Outcome in Older AML Patients: A SWOG Report,

Blood (2011) 118 (21): 3519.

https://doi.org/10.1182/blood.V118.21.3519.3519

Published: 2011

Journal Articles

Phase 2 Trial of G-CSF Priming, Clofarabine, and High Dose Cytarabine (GCLAC) for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) or Advanced Myelodysplastic Syndrome or Advanced Myeloproliferative Neoplasm,

Pamela S Becker, MD, PhD, Bruno C. Medeiros, MD, Frederick R. Appelbaum, MD, Bart Lee Scott, MD, Paul C. Hendrie, MD, PhD, Barry Storer, PhD, Sherry Pierce, RN, BS, Stephen H. Petersdorf, MD, Elihu H. Estey, MD

Blood (2011) 118 (21): 3617.

https://doi.org/10.1182/blood.V118.21.3617.3617

Published: 2011

Journal Articles

Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric and adult AML: a report from the Children's Oncology Group and SWOG

Blood (2011) 118 (17): 4561–4566.

https://doi.org/10.1182/blood-2011-04-348888

Published: 2011

Includes: Supplemental data

Journal Articles

Over-Expression of Novel IRF8 Splice Variants Is Associated with a Significant Decrease In Relapse-Free Survival In Adult AML Patients.

Era L. Pogosova-Agadjanyan, Kenneth J. Kopecky, PhD, Hana Lee, Jeanne E. Anderson, MD, John E. Godwin, MD, MS, Alan F. List, Soheil Meshinchi, MD, PhD, Vivian Oehler, MD, Stephen H. Petersdorf, MD, Cheryl L. Willman, MD, Frederick R. Appelbaum, MD, Jerald P. Radich, MD, Derek L. Stirewalt, MD

Blood (2010) 116 (21): 1679.

https://doi.org/10.1182/blood.V116.21.1679.1679

Published: 2010

Journal Articles

Evaluation of Early Discharge After Hospital Treatment of Neutropenic Fever In Acute Myelogenous Leukemia (AML).

Victor A. Chow, Kathleen Shannon Dorcy, RN, MN, Ph.C, Stephen H. Petersdorf, MD, Kelda M. Gardner, PA-C, Pamela S. Becker, MD, PhD, Roland B. Walter, MD, PhD, John M. Pagel, MD, PhD, Paul C. Hendrie, MD, PhD, Andrei R. Shustov, MD, Janis L. Abkowitz, MD, Frederick R. Appelbaum, MD, Elihu H. Estey, MD

Blood (2010) 116 (21): 3806.

https://doi.org/10.1182/blood.V116.21.3806.3806

Published: 2010

Journal Articles

Multivariate Analysis of Response and Survival After Treatment with Clofarabine, Cytarabine and G-CSF Priming (GCLAC) In Relapsed/Refractory Acute Myeloid Leukemia (AML): Comparison with Prior Experience Using Fludarabine and Cytarabine Combination Regimens.

Pamela S. Becker, MD, PhD, Hagop Kantarjian, MD, Frederick R. Appelbaum, MD, Stephen H. Petersdorf, MD, Barry Storer, PhD, Sherry A. Pierce, RN, BS, Jianqin Shan, PhD, Paul C. Hendrie, MD, PhD, John M. Pagel, MD, PhD, Andrei Shustov, MD, Derek L. Stirewalt, MD, Stefan Faderl, MD, Elizabeth Harrington, RN, Elihu H. Estey, MD

Blood (2010) 116 (21): 1065.

https://doi.org/10.1182/blood.V116.21.1065.1065

Published: 2010

Journal Articles

Prognostic Implications of the IDH1 synonymous SNP rs11554137 In Pediatric and Adult AML: a Children's Oncology Group and Southwest Oncology Group Study

Blood (2010) 116 (21): 2737.

https://doi.org/10.1182/blood.V116.21.2737.2737

Published: 2010

Journal Articles

Outcomes of Early Relapse Following Non-Myeloablative Allogeneic Transplant for Lymphoma.

Ron Ram, MD, Ted Gooley, David G. Maloney, MD, PhD, Oliver W. Press, MD, John M. Pagel, MD, PhD, Stephen H. Petersdorf, MD, Andrei R. Shustov, MD, Mary E.D. Flowers, MD, Brenda M. Sandmaier, MD, Rainer F. Storb, MD, Ajay K. Gopal, MD

Blood (2009) 114 (22): 1204.

https://doi.org/10.1182/blood.V114.22.1204.1204

Published: 2009

Journal Articles

Very late antigen-4 function of myeloblasts correlates with improved overall survival for patients with acute myeloid leukemia

Pamela S. Becker, Kenneth J. Kopecky, Adrianne N. Wilks, Sylvia Chien, John M. Harlan, Cheryl L. Willman, Stephen H. Petersdorf, Derek L. Stirewalt, Thalia Papayannopoulou, Frederick R. Appelbaum

Blood (2009) 113 (4): 866–874.

https://doi.org/10.1182/blood-2007-12-124818

Published: 2009

Includes: Supplemental data

Journal Articles

Total body irradiation, etoposide, cyclophosphamide, and autologous peripheral blood stem-cell transplantation followed by randomization to therapy with interleukin-2 versus observation for patients with non-Hodgkin lymphoma: results of a phase 3 randomized trial by the Southwest Oncology Group (SWOG 9438)

John A. Thompson, Richard I. Fisher, Michael LeBlanc, Stephen J. Forman, Oliver W. Press, Joseph M. Unger, Auayporn P. Nademanee, Patrick J. Stiff, Stephen H. Petersdorf, Alexander Fefer

Blood (2008) 111 (8): 4048–4054.

https://doi.org/10.1182/blood-2007-09-111708

Published: 2008

NARROW

Empiric Definition of Eligibility Criteria for Clinical Trials in Relapsed/Refractory AML: Analysis of 1,892 Patients from HOVON/SAKK and SWOG

A Phase I/II Study Of Fludarabine, Cyclophosphamide, Rituximab and Vorinostat Followed By Rituximab and Vorinostat Maintenance Therapy In Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia (CLL) Or Small Lymphocytic Leukemia (SLL)

A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia

Specific Features Identify Patients with Relapsed/Refractory Mantle Cell Lymphoma Benefitting From Autologous Hematopoietic Cell Transplantation.

Survival After Failure of Initial Therapy for Newly-Diagnosed or Relapsed/Refractory AML At An Academic Center: Subsequent Clinical Trial Vs. Not

Probability of Eventual CR After Course 1 of Induction Therapy for Newly-Diagnosed AML As a Function of Speed of Neutrophil and Platelet Recovery

Prognostic Import of French-American-British (FAB) System As Embedded in 2008 Revision of World Health Organization Classification of AML: Review of SWOG Data

KIT Mutations Are Rare Among Elderly AML Patients: A SWOG Report

The Pre-Transplant Mantle Cell Lymphoma International Prognostic Index Predicts Overall and Progression-Free Survival Following High-Dose Therapy and Autologus Stem Cell Transplant for Mantle Cell Lymphoma

Prevalence and Clinical Implications of IDH2 R140 and R172 Mutations in Older Adults with AML: A Report From SWOG,

DNMT3A Mutations Independently Predict Poor Outcome in Older AML Patients: A SWOG Report,

Phase 2 Trial of G-CSF Priming, Clofarabine, and High Dose Cytarabine (GCLAC) for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) or Advanced Myelodysplastic Syndrome or Advanced Myeloproliferative Neoplasm,

Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric and adult AML: a report from the Children's Oncology Group and SWOG

Over-Expression of Novel IRF8 Splice Variants Is Associated with a Significant Decrease In Relapse-Free Survival In Adult AML Patients.

Evaluation of Early Discharge After Hospital Treatment of Neutropenic Fever In Acute Myelogenous Leukemia (AML).

Multivariate Analysis of Response and Survival After Treatment with Clofarabine, Cytarabine and G-CSF Priming (GCLAC) In Relapsed/Refractory Acute Myeloid Leukemia (AML): Comparison with Prior Experience Using Fludarabine and Cytarabine Combination Regimens.

Prognostic Implications of the IDH1 synonymous SNP rs11554137 In Pediatric and Adult AML: a Children's Oncology Group and Southwest Oncology Group Study

Outcomes of Early Relapse Following Non-Myeloablative Allogeneic Transplant for Lymphoma.

Very late antigen-4 function of myeloblasts correlates with improved overall survival for patients with acute myeloid leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only